melanoma

News

Data builds behind Moderna's skin cancer vaccine

Five-year results with Moderna/MSD's melanoma jab show a 49% reduction in disease progression or death, boding well for phase 3 data later this year.

Oncology

Interview at ESMO 2025 with Inge Marie Svane

ESMO25: Immuno-therapies and translational research in oncol...

Dr Inge Marie Svane – Professor in Clinical cancer immune therapy and director of the translational research centre, CCIT, on IO Biotech's ESMO25 data

News

IO Bio plans cancer vaccine filing despite trial miss

IO Biotech's cancer vaccine Cylembio failed to hit the mark in a phase 3 melanoma trial – but the company hopes to file for approval regardless.

News

Iovance cuts staff on slower cell therapy sales growth

Iovance will slash 19% of its headcount in a restructuring that follows slower-than-expected sales growth for melanoma cell therapy Amtagvi.

Oncology

Redefining the future of melanoma treatment: Scancell's bold...

News

Scancell points to 'strong' melanoma vaccine data

Scancell has the results it was hoping for with its melanoma immunotherapy iSCIB1+ and is accelerating plans for a pivotal trial.

Data builds behind Moderna's skin cancer vaccine

ESMO25: Immuno-therapies and translational research in oncol...

IO Bio plans cancer vaccine filing despite trial miss

Iovance cuts staff on slower cell therapy sales growth

Redefining the future of melanoma treatment: Scancell's bold...

Scancell points to 'strong' melanoma vaccine data

NHS "isn't delivering equitable care for rare diseases"

Using AI-driven synthetic personas to take your insights fur...

melanoma

Editor's Picks